Revvity, Inc. (LON:0KHE)
London
· Delayed Price · Currency is GBP · Price in USD | Market Cap | 8.47B |
| Revenue (ttm) | 2.19B |
| Net Income (ttm) | 214.75M |
| Shares Out | n/a |
| EPS (ttm) | 1.74 |
| PE Ratio | 39.46 |
| Forward PE | n/a |
| Dividend | 0.22 (0.24%) |
| Ex-Dividend Date | Apr 17, 2025 |
| Volume | 12 |
| Average Volume | 2,744 |
| Open | 92.81 |
| Previous Close | 94.67 |
| Day's Range | 92.45 - 92.81 |
| 52-Week Range | 79.50 - 138.90 |
| Beta | 1.07 |
| RSI | 43.98 |
| Earnings Date | May 1, 2025 |
About Revvity
Revvity, Inc. provides health sciences solutions, technologies, and services worldwide. The company’s Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and DNA sequencing services. Its Diagnostics segment offers instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for tes... [Read more]
Financial Performance
In 2024, Revvity's revenue was $2.76 billion, an increase of 0.16% compared to the previous year's $2.75 billion. Earnings were $270.39 million, a decrease of -60.99%.
Financial numbers in USD Financial StatementsNews
Revvity to Hold Earnings Call on Monday, April 28, 2025
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced that it will release its first quarter 2025 financial results prior to market open on Monday, April 28, 2025. The Company w...
What's Going On With Revvity Stock Today?
Revvity, Inc. (NYSE: RVTY) shares are trading higher on Wednesday. The company announced today that the U.S. Food and Drug Administration has approved its Auto-Pure 2400 liquid handling platform, int...
Revvity gets FDA nod for its automated tuberculosis test
Revvity Secures FDA Approval for Improved Automated Latent Tuberculosis Test
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced that the U.S. Food and Drug Administration (FDA) has approved the Auto-Pure 2400 liquid handling platform with the T-SPOT™....
Revvity Signals Software Unveils Unified Data Platform to Accelerate Drug Discovery
WALTHAM, Mass.--(BUSINESS WIRE)--Today, Revvity, Inc. announced that its software and informatics division, Revvity Signals Software, will launch its Signals One™, a unified software platform evolved ...
Is Revvity Gaining or Losing Market Support?
Revvity's (NYSE: RVTY) short percent of float has risen 8.68% since its last report. The company recently reported that it has 5.18 million shares sold short , which is 5.76% of all regular shares th...
Maryland Rep. April McClain Delaney Sold Over $54K Worth of A.O. Smith Stock: Here's What You Should Know
A March filing shows that Representative April McClain Delaney reported a sale in A.O. Smith (NYSE: AOS), valued between $54,012 and $285,000. The transaction date is listed as March 20, 2025, with t...
Revvity Expands Alliance with Genomics England to Drive Research into Newborn Genomic Sequencing in England
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity announced an agreement with Genomics England to further collaborate on the Generation Study by providing sequencing services.
PerkinElmer Acquires Project Farma, Expanding Its OneSource Professional Services Offering for the Life Sciences Industry
SHELTON, Conn.--(BUSINESS WIRE)--PerkinElmer, a global leader in analytical solutions and specialized services for (bio)pharma, applied and food markets, today announced the acquisition of Project Far...
Revvity's EUROIMMUN Receives CE Mark for Novel Measles Antibody Detection Assay
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced the launch of EUROIMMUN's CE-marked Anti-Measles Virus ELISA 2.0 (IgG) to support the diagnosis of a measles virus infectio...
Revvity: Acquisitions In High-Growth Sectors, Excellent Debt Levels Create Notable Growth Potential
Revvity Wins Permanent Injunction Enforcing Agreements with Cloud Software Group
WALTHAM, Mass.--(BUSINESS WIRE)--Today, Revvity, Inc. (NYSE: RVTY) announced that the Massachusetts Superior Court has ruled in its favor and will issue a permanent injunction to enforce Revvity's rig...
Revvity to Present at Upcoming Investor Conferences
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced it will present at the following investor conferences in March 2025: 46th Annual Raymond James Institutional Investor Confe...
T. Rowe Price Investment Management, Inc. Increases Stake in Revvity Inc.
T. Rowe Price Investment Management, Inc. Increases Stake in Revvity Inc.
Revvity, Inc. 2024 Q4 - Results - Earnings Call Presentation
Revvity anticipates 3%-5% organic growth in 2025 amid market stabilization
Revvity, Inc. (RVTY) Q4 2024 Earnings Call Transcript
Revvity forecasts 2025 revenue, profit below estimates amid weak biotech spending
Medical equipment maker Revvity forecast full-year profit and revenue for 2025 below Wall Street estimates on Friday, as it expects soft demand for its products and services used in drug research.
Revvity reports mixed Q4 earnings; initiates FY 2025 guidance
Revvity press release (RVTY): Q4 Non-GAAP EPS of $1.42 beats by $0.04. Revenue of $729M (+4.7% Y/Y) misses by $1.07M. Adjusted operating profit margin was 30.3% as a percentage of adjusted
Revvity Announces Financial Results for the Fourth Quarter and Full Year of 2024
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY) today reported financial results for the fourth quarter and full year ended December 29, 2024. Fourth Quarter 2024 The Company reported GAAP...
Revvity Q4 2024 Earnings Preview
Revvity declares $0.07 dividend
Revvity Board Declares Quarterly Dividend
WALTHAM, Mass.--(BUSINESS WIRE)--The Board of Directors of Revvity (NYSE: RVTY), today declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on May 9, 2025...
Revvity Ignites Scientific Breakthroughs at SLAS2025
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. is set to unveil its groundbreaking new Phenologic.AI™ software at SLAS2025 in San Diego, January 27-29. Designed to redefine cellular imaging workflows ...
Revvity and Element Biosciences Collaborate to Advance Sequencing-based IVD Neonatal Testing
WALTHAM, Mass. & SAN DIEGO--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced a strategic agreement to commercialize an in vitro diagnostic (IVD) workflow solution for neonatal sequencing, ...